C-reactive protein and fibrinogen of bedridden older patients in a six-month vitamin D supplementation trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

To elucidate the association between vitamin D status, C-reactive protein (CRP) and fibrinogen.

Who Took Part

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Secondary analysis of a randomised double-blind placebo controlled trial.

Four longterm care hospitals (1215 beds) in Helsinki, Finland.

Plasma 25-hydroxyvitamin D (25-OHD), parathyroid hormone (PTH), high sensitive CRP, fibrinogen, amino-terminal propeptide of type I procollagen (PINP), and carboxy-terminal telopeptide of type I collagen (ICTP) were measured.

What Was Measured

The subject headings attached to it are C-Reactive Protein, Collagen Type I, Dietary Supplements, Fibrinogen, Finland, Frail Elderly and Geriatric Assessment.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (The journal of nutrition, health & aging), a journal based in France.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.